ZEALAND PHARMA A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 657.5 DKK | -0.38% |
|
+4.37% | +76.18% |
| Apr. 04 | U.S. Futures Up, European Stocks Flat as Powell Reiterates Room for Rate Cuts This Year | DJ |
| Mar. 20 | Zealand Pharma A/S Approves Appointments to the Board | CI |
Presenter SpeechCharles Mabbutt (Analysts)Good morning, everyone. I'm Charlie Mabbutt, Pharmac...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity.
At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Calendar
2024-05-16
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
660
DKK
Average target price
782
DKK
Spread / Average Target
+18.48%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +76.18% | 5.94B | |
| +3.10% | 106B | |
| +7.02% | 23.47B | |
| -14.83% | 21.9B | |
| -7.05% | 18.77B | |
| -38.55% | 17.85B | |
| -9.39% | 16.78B | |
| +6.47% | 14.41B | |
| +34.83% | 12.86B | |
| +315.91% | 8.78B |
- Stock Market
- Equities
- ZEAL Stock
- News Zealand Pharma A/S
- Transcript : Zealand Pharma A/S Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-12-2023 11